Emanuel Petricoin 3rd
Overview
Explore the profile of Emanuel Petricoin 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
908
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, et al.
Mol Cell Proteomics
. 2024 Oct;
23(12):100870.
PMID: 39461475
Despite of massive emergence of molecular targeting drugs, the mainstay of advanced gastric cancer (GC) therapy is DNA-damaging drugs. Using a reverse-phase protein array-based proteogenomic analysis of a panel of...
2.
Dickinson S, Vaishampayan P, Jandova J, Ai Y, Kirschnerova V, Zhang T, et al.
JID Innov
. 2024 Feb;
4(2):100255.
PMID: 38328594
The immune checkpoint ligand PD-L1 has emerged as a molecular target for skin cancer therapy and might also hold promise for preventive intervention targeting solar UV light-induced skin damage. In...
3.
Micaily I, Blais E, Carhart R, Lam S, Cohen S, Cannaday S, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2200648.
PMID: 38085059
Purpose: Pancreatic adenocarcinoma is an aggressive disease with poor clinical outcomes. Primary pancreatic tumors originating from the head of the pancreas (H) have different prognostic implications than tumors arising from...
4.
Wood K, Nussbaum D, Martz C, Waters A, Barrera A, Rutter J, et al.
Res Sq
. 2023 Nov;
PMID: 37961649
Acquired resistance remains a major challenge for therapies targeting oncogene activated pathways. KRAS is the most frequently mutated oncogene in human cancers, yet strategies targeting its downstream signaling kinases have...
5.
Pishvaian M, Blais E, Brody J, Rahib L, Lyons E, De Arbeloa P, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-10.
PMID: 35100730
Purpose: Up to 25% of pancreatic adenocarcinomas (PDACs) harbor mutations in the homologous recombination DNA damage response (HR-DDR) pathway. Although known to affect responsiveness to DNA-damaging chemotherapy, the prognostic relevance...
6.
Petricoin 3rd E, Wulfkuhle J, Howard M, Pierobon M, Espina V, Luchini A, et al.
Adv Exp Med Biol
. 2019 Dec;
1188:1-19.
PMID: 31820380
RPPA technology has graduated from a research tool to an essential component of clinical drug discovery research and personalized medicine. Next generations of RPPA technology will be a single clinical...
7.
Nadella S, Burks J, Huber M, Wang J, Cao H, Kallakury B, et al.
Pancreas
. 2019 Jul;
48(7):894-903.
PMID: 31268978
Objective: The KRAS gene is the most frequently mutated gene in pancreatic cancer, and no successful anti-Ras therapy has been developed. Gastrin has been shown to stimulate pancreatic cancer in...
8.
He S, Fu Y, Guo J, Spear M, Yang J, Trinite B, et al.
Sci Adv
. 2019 Jan;
5(1):eaat7911.
PMID: 30662943
A functional HIV cure requires immune reconstitution for lasting viremia control. A major immune dysfunction persisting in HIV infection is the impairment of T helper cell migration and homing to...
9.
Pishvaian M, Petricoin 3rd E
Clin Cancer Res
. 2018 Dec;
24(24):6612.
PMID: 30552237
No abstract available.
10.
Pishvaian M, Bender R, Matrisian L, Rahib L, Hendifar A, Hoos W, et al.
Oncotarget
. 2017 Nov;
8(48):83446-83456.
PMID: 29137355
Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies. However, a better understanding of the...